UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
  
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the month of May 2020
 
 
Commission File Number:  001-39034
 
 
 BELLUS HEALTH INC.
 (Name of registrant)
 
 275 Armand-Frappier Blvd.
Laval, Québec
H7V 4A7
Canada
 (Address of principal executive offices)



 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 
 ☐   Form 20-F
 ☒   Form 40-F
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
  

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  BELLUS Health Inc.  
     
     
       
Date: May 28, 2020
By:
/s/ François Desjardins  
    Name:  François Desjardins  
    Title:    Vice President, Finance  
       




Form 6-K Exhibit Index
 
Exhibit Number
 
Document Description
 
 
 
 
     

 
Exhibit 99.1
   
 
BELLUS Health Inc.
275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V 4A7
   


BELLUS Health to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

LAVAL, Quebec, May 28, 2020 – BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference.

Presentation Details:

Event: Jefferies Virtual Healthcare Conference
Date: Tuesday, June 2, 2020
Time: 1:30 p.m. EDT
A live webcast of the fireside chat may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast will be available on the Company’s website.
About BELLUS Health
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.
FOR MORE INFORMATION, PLEASE CONTACT:
Danny Matthews
Director, Investor Relations and Communications
917-828-0414
danny@bellushealth.com

Source: BELLUS Health Inc.